Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Leukemia and Lymphoma

• Publication date

  2016-05-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2015.1096356PMID 26397936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

  2015cited by this paper
• Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma

  2015cited by this paper
• Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

  2014cited by this paper
• Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma

  2013cited by this paper
• Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

  2011cited by this paper
• R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.

  2009cited by this paper
• The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

  2004cited by this paper
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

  2004cited by this paper
• BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells

  2003cited by this paper
• Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

  2003cited by this paper

• Use of doxorubicin is not associated with hemolytic complications in severely G6PD deficient patients with lymphoma

  2025cites this paper
• Diffuse Large B-Cell Lymphoma in the Older and Frail Patient

  2025cites this paper
• SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.

  2024cites this paper
• "Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country".

  2022cites this paper
• R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

  2022cites this paper
• Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist

  2021cites this paper
• Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities

  2021cites this paper
• Diffuse large B‐cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

  2021cites this paper
• Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.

  2021cites this paper
• Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches

  2020cites this paper
• Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective.

  2020cites this paper
• Approaches to aggressive B-cell lymphomas in less fit patients.

  2020cites this paper
• The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma

  2019cites this paper
• Treatment of diffuse large B‐cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP‐16)

  2019cites this paper
• Extranodal Non-Hodgkin’s Lymphoma at Maxillofacial Bone: A Case Report

  2019cites this paper
• Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma - Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007-2015.

  2019cites this paper
• The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment

  2019cites this paper
• Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

  2018cites this paper
• Curing diffuse large B-cell lymphomas in elderly patients.

  2018cites this paper
• Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

  2017cites this paper
• Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

  2017cites this paper
• Substitution of doxorubicin with etoposide in the treatment of lymphomas

  2017cites this paper
• State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.

  2016cites this paper